Your genes may hold the key to which diabetes drug works best
NCT ID NCT07120828
Summary
This study aimed to understand why some people respond better than others to certain diabetes medications. Researchers followed 260 obese adults with newly diagnosed Type 2 diabetes for six months, giving them either empagliflozin, dapagliflozin, or standard care. The main goal was to see if differences in a specific gene (CYP8B1) could explain changes in weight, cholesterol, blood sugar, and other health markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epu
Erbil, Kurdistan, 44001, Iraq
Conditions
Explore the condition pages connected to this study.